Presentation of intracranial meningiomas in Johannesburg (a 12-month prospective study at Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani Baragwanath Hospital) by Ibebuike, Kaunda Emeka
PRESENTATION OF INTRACRANIAL MENINGIOMAS IN JOHANNESBURG (A 
12-MONTH PROSPECTIVE STUDY AT CHARLOTTE MAXEKE JOHANNESBURG 
ACADEMIC HOSPITAL AND CHRIS HANI BARAGWANATH HOSPITAL) 
 
 
 
by 
 
 
Kaunda Emeka Ibebuike 
392882 
 
 
A research report submitted to the 
Faculty of Health Sciences 
University of the Witwatersrand, Johannesburg 
in partial fulfillment of the requirements for the degree of 
 
Master of Medicine in the specialty of in Neurological Surgery 
 
 
 
 
Johannesburg, 2011 
  
 
ii 
DECLARATION 
I, Dr Kaunda Emeka Ibebuike, declare that this research report is my own work. It is being 
submitted for the degree of Master of Medicine in the University of the Witwatersrand, 
Johannesburg. It has not been submitted in part or in full for any other degree or examination 
at this or any other University, nor has it been submitted elsewhere for publication. 
……… …………….. 
…25th...day of…October…2011 
 
  
 
iii 
DEDICATION 
This research report is dedicated to:                                                                       
The Almighty God through whom all blessings come        
My family, especially my wife, for her patience, understanding and support since the 
first time we met.  
  
 
iv 
PRESENTATION ARISING FROM THIS STUDY 
1. Intracranial meningiomas in Johannesburg 
Presented at the 21
st
 Biennal Congress of the Society of Neurosurgeons of South Africa, 
Johannesburg, 19-22 September, 2010 
SESSION EIGHT 21st September 2010 
TOPIC: Tumours TIME: 16h30 – 18h00pm (1½ hour) 
Chairperson: Prof. HB. Hartzenberg Panel: Prof. A Kaye, Dr. S. Nadvi 
TIME ACTIVITY/TOPIC PRESENTER 
16:30 – 16:50 Management of giant pituitary tumours Prof P Semple 
16:50 – 17:00 Extracranial Ependymoma Dr T Kuruvilla 
17:00 – 17:15 Surgical treatment of pineal region tumours: Our experience of 9 cases  
DrVN Bikmullin 
17:15 – 17:25 Review of pituitary tumours over 10 years Dr K Matshana 
17:25 – 17:35 Intracranial meningiomas in Johannesburg Dr KE Ibebuike 
17:35 – 17:45 A1 segment aneurysm presenting as pituatory apoplexy Dr OA Labeodan 
17:45 - 18:00 DISCUSSION 
 
 
 
  
 
v 
ABSTRACT 
The study aimed at determining the relative frequency of intracranial meningiomas among 
primary brain tumours; age, gender, ethnic distributions and their mode of presentation. 
This was a 12-month prospective study of 48 consecutive patients with histologically proven 
intracranial meningiomas seen at CMJAH and CHBH.  
Meningiomas accounted for 33.8% of all primary brain tumours. The mean age of patients was 
45.7 ± 10.1 years with a female-to-male ratio of 3.8:1. The peak age range at presentation was 
in the fifth (41.7%) and sixth (27.1%) decades. The highest frequency was in Blacks (75%) 
and Sotho ethnic nationality (27.1%). The mean duration of symptoms and signs was 24.4 ± 
26.5 months. The commonest presentations were headache (87.5%), visual impairment 
(64.6%), seizures (43.8%), motor deficit (37.5%), convexity meningiomas (25%), 
meningothelial subtypes (39.6%) and WHO grade I tumours (81.3%). 
This study showed that meningiomas are the most common primary intracranial tumours 
among adults in our environment. 
 
 
 
 
 
 
  
 
vi 
ACKNOWLEDGMENTS 
I thank the Almighty God for giving me good health and life, and for guiding me all through 
this work. 
I am profoundly grateful to my supervisors, Dr. John Ouma and Dr. Pascale Willem, for their 
help and relentless guidance with this study. My very special thanks to my head of 
department, Prof. Rasik Gopal, whose encouragement and support since I commenced this 
work remained a great source of strength during several challenging moments in the course of 
the study. I also wish to express my appreciation to the entire consultants and registrars in the 
Department of Neurosurgery for their encouragement, understanding and inputs. I am grateful 
to the consultants, registrars and staff of Histopathology Department, Charlotte Maxeke 
Johannesburg Academic Hospital and Chris Hani Baragwanath Hospital, for their assistance, 
support and encouragement.  My special thanks to the Faculty Research Office for the various 
research/statistical workshops and writing skills that helped in guiding me through this study. I 
am grateful to Mr. Sass Starlen, who helped with the installation of useful statistical software 
for data analysis, and to Mrs Junia Mthombeni who helped me with secretarial assistance 
whenever I needed her support. I am immensely grateful to the Imo State Government of 
Nigeria and the Imo State University Teaching Hospital, Orlu, for providing me with research 
grant to enable me weather the financial challenges for the study  
Finally, I remain indebted to my wife, Mrs. J. E. Ibebuike, my children (David, John, Ruth and 
Caleb), my parents, siblings, and in-laws whose encouragement, understanding and support 
remain sources of inspiration to me. 
  
 
vii 
TABLE OF CONTENTS 
TITLE PAGE i 
DECLARATION ii 
DEDICATION iii 
PRESENTATION ARISING FROM THIS STUDY iv 
ABSTRACT v 
ACKNOWLEDGEMENTS vi 
TABLE OF CONTENTS vii 
LIST OF FIGURES Ix 
LIST OF TABLES x 
NOMENCLATURE xi 
1.0 INTRODUCTION 1 
1.1 Literature review 3 
1.1.1 Incidence 3 
1.1.2 Sex 4 
1.1.3 Race 4 
1.1.4 Age 5 
1.1.5 Presentation and magnitude of the problem 6 
1.2 Justification for the study 7 
1.3 Study objectives 10 
1.3.1 General objectives 10 
1.3.2 Specific objectives 10 
2.0 METHODS 11 
  
 
viii 
2.1 Research design 11 
2.2 Place and period of study 11 
2.3 Patient selection 11 
2.4 Inclusion criteria 11 
2.5 Exclusion criteria 11 
2.6 Limitations 12 
2.7 Instrument 12 
2.8 Data analysis 13 
3.0 RESULTS 14 
4.0 DISCUSSION 28 
4.1 Relative frequency 28 
4.2 Sex 29 
4.3 Race 30 
4.4 Age 30 
4.5 Clinical presentation 32 
4.6 Neuro-radiology 35 
4.7 Neuro-pathology 41 
5.0 CONCLUSION 42 
6.0 RECOMMENDATIONS 45 
APPENDIX A  Proforma of study 46 
APPENDIX B  Patient information sheet 50 
APPENDIX C  Informed consent form 53 
REFERENCES 57 
 
  
 
ix 
LIST OF FIGURES 
Figure 3.1 Mode of admission 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
x 
LIST OF TABLES 
Table 3.1 Initial assessment of intracranial neoplasms entered for the study 14 
Table 3.2 Patients initially assessed as meningioma but with biopsies negative for 
meningioma 
14 
Table 3.3 Reason for non-operative intervention 15 
Table 3.4 Relative frequency of intracranial meningiomas among primary 
intracranial tumours 
16 
Table 3.5 Age of patients at presentation 17 
Table 3.6 Gender, race and ethnic nationality (home language) distribution 18 
Table 3.7 Presenting symptoms and signs 19 
Table 3.8 Characteristics of symptoms and signs at presentation and their 
duration 
21 
Table 3.9 Anatomic location of intracranial meningiomas 23 
Table 3.10 Radiological findings in patients with intracranial meningioma 24 
Table 3.11 Histological subtypes and grading of intracranial meningiomas 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
xi 
NOMENCLATURE 
CT scan - Computed tomography scan 
MRI - Magnetic resonance imaging 
USA - United States of America 
US - United States 
USSR - Union of Soviet Socialist Republics 
CMJAH - Charlotte Maxeke Johannesburg Academic Hospital 
CHBH - Chris Hani Baragwanath Hospital  
GCS - Glasgow Coma Score 
FNS - First Noticed Symptoms 
NCS - Neurosurgical Consultation Symptoms 
CP Angle/CPA- Cerebello-pontine angle 
  
 
1 
1.0 INTRODUCTION 
Meningiomas are tumours that develop from meningothelial cells of the arachnoid layer. 
Although they are a common central nervous system neoplasm and have an interesting 
long history which predates modern neurosurgery, they remain under-studied and under-
reported (1, 2). Meningioma was first described in 1614 by Felix Paster (1, 3), and one 
hundred and sixty years afterwards, Louis (1, 4) published a series on the pathology of a 
“fungating tumour of the dura mater”. The 18th century witnessed attempts at surgical 
resection and in 1887, W.W. Keen performed the first successful excision of a meningioma 
in the United States (1, 5, 6).  
Later in the 20
th
 century Harvey Cushing (1, 5, 7, 8) adopted the term meningioma as a 
single description for the different pathological types of tumours which arise from the 
meninges. Since then there has been increasing scientific and surgical interest in 
meningiomas. In 1922, Cushing wrote: “There is today nothing in the whole realm of 
surgery more gratifying than the successful removal of a meningioma with subsequent 
perfect functional recovery, especially should a correct pathological diagnosis have been 
previously made. The difficulties are admittedly great, sometimes insurmountable, and 
though the disappointments still are many, another generation of neurological surgeons 
will unquestionably see them largely overcome” (1, 7, 8). These words are very much 
fulfilled today. 
Advances in neuroimaging have made the preoperative diagnosis of a meningioma almost 
certain. However, some meningiomas with an aggressive course, potential for recurrence 
or resistance to available treatment modalities are still a dilemma.  The biologically 
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complex nature of meningiomas together with the challenges they present clinically and 
surgically, coupled with the rewarding potential for cure make them of immense interest to 
neurosurgeons and neuroscientists (9). 
An overview of the descriptive epidemiology and presentation of this most intriguing 
disease will be presented in the literature review.  
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1.1 LITERATURE REVIEW 
1.1.1 Incidence 
Meningiomas are the most common primary intracranial neoplasms in adults (10). Though 
early combined results from several large hospital-based brain tumour studies showed that 
the incidence of meningiomas is approximately 20% of all intracranial tumours (11, 12), 
they are estimated to constitute between 13 and 26% of all intracranial neoplasms (13). 
Cushing (7, 12, 14) in 1938 found 13.4% while Zimmerman (12, 15) in 1969 reported 
27.3% prevalence rate for meningiomas. The highest incidence of meningiomas was noted 
by Percy et al (12, 16) in a population based  review of records from 1935 to 1958. In their 
study meningiomas accounted for 38% of primary intracranial tumours, though this 
contrasts with another population based clinical study performed in Manitoba, Canada 
from 1980 to 1985 where meningiomas accounted for 22% of primary intracranial tumours 
(7, 12, 17). The overall incidence of meningiomas in the Manitoba study was 2.3/100,000 
(7, 12) 
More recent studies show consistently high incidence of meningiomas, accounting for 25% 
of all intracranial neoplasms diagnosed in the United States (18), approximately 20% of all 
intracranial tumours in males and 38% in females (12, 18, 19). The estimated prevalence of 
meningiomas was approximately 97.5/100,000 in the United States (18, 20). A recent 
study in Nigeria, West Africa by Idowu et al (21) supports earlier findings that 
meningiomas are the most common primary intracranial neoplasms in adults  with an 
incidence of 35% in their study. 
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1.1.2 Sex 
Whereas intracranial tumours as a whole show a predominance in men (12, 21), 
meningiomas have a 2:1 female-to-male ratio in adults (7, 12, 13, 22). Interestingly, the 
Manitoba meningioma study showed no predominance in women in their fourth decade of 
life (7, 12, 17). Female predominance was noticed only after the fifth decade, and when 
readjusted after the sixth decade was 1:1 (7, 12, 17). Other studies, however, show that the 
difference is greatest in the older age group (23-25). An interesting finding among African 
groups in early reports was equal gender distribution or a male predominance (12, 26). 
However, recent African based studies are not in keeping with that (21, 27, 28). 
1.1.3 Race 
The prevalence of intracranial meningiomas displays racial/ethnic differences as can be 
seen between Caucasians, Africans and African-Americans. Meningiomas are more 
common in Africa than in America and Europe (29, 30) and accounts for nearly 30% of all 
primary intracranial tumours (29). In a Los Angeles County population-based study, 
Africans had a higher incidence than the Caucasian Americans(average, 3.1/100,000 
compared to 2.3/100,000 respectively) (12, 31, 32). In this study, Asians were found to 
have the lowest rates though the differential rates between Asians and whites was less 
particularly among women (12, 31). On a larger scale, this is supported by a comparison of 
relative frequency of intracranial meningiomas in different countries including USA, 
Sweden, Iran, India, Japan and Germany (33). India had the lowest rate of 10.3% of 
meningiomas while Iran had the highest rate(29%) (33).  
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1.1.4 Age 
The incidence of meningiomas increases with age (11, 12, 18). The annual incidence per 
100,000 people ranges from 2 to 7 for women and from 1 to 5 for men (11, 12). In a study 
by Rohinger et al (12, 34), the incidence for males peaked in the seventh decade at 
6.0/100,000 and for females in the eight decade at 9.5/100,000. Idowu et al (21) in their 
study noted that meningiomas accounted for 23% of all intracranial tumours in all age 
groups, and 35% in adults. Meningiomas are rare in children (7, 29, 35) and even more rare 
in infants (7, 12, 29). They account for 1-4% of all childhood (<18 years) primary brain 
lesions (7, 12, 35). They differ from those in adults and the childhood tumours in several 
respects including equal distribution between boys and girls (7, 35) or a male 
predominance (71%) especially in infants (7, 12). The average age at presentation is 10.9 
years compared to 5.5 years for other Paediatric brain tumours (12). The incidence of 
intraventricular (17%) and posterior fossa (19%) meningiomas are higher in childhood 
than in adults as well as a significantly higher incidence (32% compared to 10%) of 
tumour calcification, sarcomatous elements and recurrence (7, 12). They, however, show 
similarities with adult meningiomas or other Paediatric brain tumours in the frequent 
(23%) association of neurofibromatosis with multiple intracranial tumours as well as 
clinical manifestations of increased intracranial pressure, visual disturbance, cranial nerve 
involvement or seizures (7, 12). 
The incidence of intracranial meningiomas has also been noted to increase with time (12, 
36). However, these increased rates may reflect improved diagnostic imaging modalities 
and increasing life expectancy of the general population (2, 10, 12) 
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1.1.5 Presentation and Magnitude of the Problem 
Meningiomas are slow growing, usually benign and can remain clinically asymptomatic 
for years (29, 37). They challenge the neurosurgeon at every step and management 
decisions in asymptomatic presentations may be difficult (1). In some locations in the 
brain, meningiomas are problematic neoplasms which are difficult, disabling and 
ultimately fatal (1).  
The mean duration of symptoms is approximately 15 months and 30% of complaints are 
less than 3 months in duration (38). They are associated with distressful clinical symptoms 
including loss of vision, dementia, headaches and seizures (1, 18). The relatively slow rate 
of growth for some meningiomas may lead to subtle losses of neurological function over 
time including speech difficulties such as finding words, changes in concentration abilities 
and paralysis of an arm or leg causing problems with writing, or walking (1, 18). It is 
reported that up to 30% of meningioma patients cannot read, write, drive or think at the 
same level as before their diagnosis (1). This highlights the subtle disabling outcomes 
associated with meningiomas. It is therefore important to identify means of defining 
individuals at risk as well as potential areas for rehabilitation services for such patients 
(18). 
Though most meningiomas are benign, about 20% demonstrate clinically aggressive 
features which leads to significant morbidity and mortality (2). These categories of 
meningiomas frequently recur and expose patients to multiple surgical resections (39). In 
addition to the burden of suffering related to its disabilities and the attendant loss of 
productivity, meningiomas therefore constitute a major socioeconomic problem as well as 
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an important neurosurgical problem. And although intracranial meningiomas are usually 
benign and often cured after complete surgical excision, they still exhibit significant 
diagnostic and treatment challenges (9, 22, 40). 
1.2 JUSTIFICATION FOR THE STUDY 
Though meningiomas are common intracranial neoplasms, they remain under-studied and 
under-reported with comparatively limited research in the past regarding their 
epidemiology (2, 10). However, over the years there has been growing interest in 
meningiomas with new questions and challenges especially in epidemiology, radiology, 
pathology, genetics and treatment (9, 10).  
Worldwide there has been consistent increase in the incidence of meningiomas and; also 
studies confirm increase in incidence with age as well as a female preponderance (18, 21). 
In several industrialised countries in the late 1970s and early 1980s there was an observed 
increase in the incidence of meningiomas (38). In Denmark, Finland, Norway and Sweden, 
the combined incidence increased from 1.4 to 1.9 per 100,000 among men and 2.6 to 4.5 
per 100,000 among women (38) confirming an increase with age and a female 
preponderance. In a study by Elia-Pasquet (41) in Gironde, France, the incidence of 
intracranial meningiomas was 4 per 100,000 in those younger than 50 years and 7 to 10 per 
100,000 in those older than 50 years. Christensen et al (36) in a 55 year study in Denmark 
reported 3.9 fold increase in the incidence of meningiomas from 1943 to 1997. In contrast, 
the incidence of gliomas increased by 1.7 fold during the same period. They noted in their 
study that improved diagnostic modalities have reached their maximum for gliomas. But 
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the same was not observed for meningiomas, and this may be an indication that under 
reporting of meningiomas is still present. 
In addition to more sensitive diagnostic tools, the increased incidence of meningiomas may 
be related to increased exposure to environmental risk factors (10). It is reported that the 
high incidence of meningiomas in Iran (29%) is thought to be partly due to the late effects 
of mild doses of radiation of the scalp that some patients received in early childhood for 
treatment of ring worm of the scalp (33). Hence with increased life expectancy and 
availability of modern diagnostic tools, the incidence of meningiomas is expected to 
increase. 
However, the advent of better imaging techniques has enabled earlier identification of 
these tumours in asymptomatic patients or patients with only a mild seizure as the 
presenting complaint(1), hence aiding reduction in morbidity and mortality. Whereas these 
new diagnostic tools including computed tomography scan (CT scan) and magnetic 
resonance imaging (MRI) are available in our environment, these tumours remain under 
reported. A closer look at the presentation of this disease in our environment is therefore 
considered worthwhile. This will increase awareness of this slow growing, mostly benign, 
potentially curable and highly prevalent disease among clinicians to aid early detection, 
treatment and subsequent reduction in morbidity and mortality associated with late 
presentation in our environment. 
The information relating to the highest incidence of meningioma being in Africa (12, 30)  
adds to the challenge for a closer look at the presentation of this disease. This is in addition 
to the observation of a lack of such study in our environment. As our population ages due 
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to increase in our life expectancy, a closer look at this disease is therefore justified. 
Meningioma presents geographical and ethnic differences (18, 30). South Africa being 
peculiarly multiracial and multiethnic presents an ideal environment for studying the 
presentation of intracranial meningiomas. It is hoped that this will help in the advancement 
of knowledge for intracranial meningiomas both in South Africa and in the Southern 
Africa subregion. This may also aid health planners in their search for information about 
disease patterns, particularly about the prevalence of those conditions likely to make a high 
demand on hospital services.  
Currently, there is growing interest in prospective studies on meningiomas (10). It is 
therefore hoped that this prospective study on the presentation of intracranial meningiomas 
in Johannesburg will be a worthwhile contribution to the renewed research endeavour on 
meningiomas. It is also probable that this research endeavour will eventually translate into 
better understanding and improved survival prospects for the few sufferers of the clinically 
aggressive and malignant forms of this disease. 
It is hoped that with the increase in awareness of intracranial meningiomas expected from 
this study, there will be early detection and early treatment of intracranial meningiomas in 
our environment with resultant improved quality of life and survival rates in our patients. 
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1.3 STUDY OBJECTIVES 
1.3.1 General Objectives 
The aim of the study is to determine the presentation of Intracranial Meningiomas as seen 
at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and the Chris Hani 
Baragwanath Hospital, Johannesburg (CHBH). 
1.3.2 Specific Objectives 
1. To determine the relative frequency of intracranial meningiomas among primary 
intracranial tumours. 
2. To determine the age, gender, racial and ethnic distribution at presentation in 
patients with intracranial meningiomas. 
3. To determine the mode of presentation of intracranial meningiomas in 
Johannesburg. 
4. To note and make comparison with intracranial tumours that satisfied the criteria 
for inclusion in this study of intracranial meningiomas but which had negative 
biopsies. 
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2.0 METHODS 
2.1 Research Design 
A descriptive prospective study design was used. 
2.2 Place and Period of Study 
This prospective study was carried out at the Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) and the Chris Hani Baragwanath Hospital (CHBH), Johannesburg, 
over a period of 12 months from 13th July 2009 to 12th July 2010. Approval for the study 
was obtained from the Human Research Ethics Committee (Medical). 
2.3 Patient Selection 
Consecutive patients seen at the CMJAH and CHBH, Johannesburg with histologically 
proven intracranial meningiomas over a 12 month period were recruited into the study. 
2.4 Inclusion Criteria 
Criteria for inclusion in the study were as follows: 
a) Patients with clinically and radiologically suspicious intracranial meningiomas. 
However, 5 patients with intracranial tumours clinically and radiologically not 
suspicious for meningioma but with histological diagnosis of meningioma were 
entered for the study. 
b)  Patients with biopsies of intracranial tumours positive for meningioma. 
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2.5 Exclusion Criteria 
a) Patients with intracranial tumours whose clinical and radiological features were not 
suspicious for meningioma. 
b) Patients with intracranial tumours whose clinical and radiological features were 
suspicious for meningioma, but who either declined operative intervention or did 
not have their tumours resected whatever the reason for such decision. 
2.6 Limitations 
a) Clinical and radiological diagnostic features of intracranial meningiomas are clear.  
However, management decisions excluded some patients from operative 
intervention. These patients, in addtion to patients who declined operative 
intervention limited the number of patients with biopsies positive for meningioma. 
b) In addition, patients with clinical and radiological features of intracranial 
meningioma who died before a final diagnosis also limited the number of patients 
with biopsies positive for meningioma. 
2.7 Instrument 
An investigator-administered questionnaire (Appendix A) designed to record details of 
patient’s personal record and clinical data as well as findings from relevant investigations 
was used. Every new patient was clerked by the author following the order on the pro 
forma after obtaining informed consent (Appendix C). The patient was then investigated 
following the standard investigative protocol for intracranial neoplasms including CT scan 
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and or MRI. Following clinical and radiological assessment treatment was instituted. 
Treatment was on outpatient basis for some patients on account of age and mild symptoms 
such as seizures and, which are amenable to control with drugs. Patients who required 
neurosurgical operative intervention were treated as in-patients. All specimens removed at 
operative intervention were subjected to histology for a final diagnosis. 
2.8 Data Analysis 
The data obtained was analyzed by the use of computer aided statistical analysis of the 
variables. Epi Info
TM 
2008 was used to analyze variables. Epi Info is a Database and 
Statistics Program for epidemiology on microcomputers designed for Public Health 
Professionals. It was developed by the Center for Diseases Control and Prevention (CDC), 
Atlanta, Georgia. Simple statistical calculations such as mean, median, frequency, 
percentages and standard deviation of variables were worked out. Statistical diagrams such 
as tables and figures were created to highlight relevant findings.  
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3.0 RESULTS 
During the 12 months study period, 69 patients were initially entered for the study at the 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and the Chris Hani 
Baragwanath Hospital (CHBH), Johannesburg. All patients were seen as in-patients. 
Fourty eight of these patients had histologically confirmed intracranial meningioma with 
the hospital distribution as 27 patients at CHBH and 21 patients at CMJAH. 
Table 3.1: Initial assessment of intracranial neoplasms entered for the study 
 
Diagnosis                                Number of patients                        Percent 
Meningioma     64    92.8% 
Pituitary tumour    3    4.3% 
Glioma     1    1.4% 
Haemangiopericytoma   1    1.4% 
Total      69    100% 
Sixty four patients (92.8%) were initially assessed during preoperative work up as 
meningiomas, 3 (4.3%) as pituitary tumours and 1 (1.4%) each as glioma and 
haemangiopericytoma. 
Table 3.2: Patients initially assessed as meningioma but with biopsies negative for 
meningioma  
 
Histological Diagnosis Number of patients                     Percent  
Metastatic tumour     3   33.3% 
Haemangioblastoma     1   11.1% 
PCNSL      1   11.1% 
Myeloma      1   11.1% 
Meningeal haemangiopericytoma   1   11.1% 
Pituitary tumour     1   11.1% 
Mycobacterial infection    1   11.1% 
Total       9   100% 
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Patients initially assessed as meningioma after clinical and radiological assessment but 
with biopsies negative for meningioma were nine in number. Metastaic tumours were 3 
(33.3%) whereas the rest were 1 (11.1%) each including mycobacterial infection. 
Table 3.3: Reasons for non-operative intervention 
Reasons for Non-operative Intervention               Number of patients         Percent 
Patient declines operative intervention   4  33.3% 
Elderly + clinical debilitation from primary diseae  2  16.7% 
Clinical debilitation from extensive primary diseae  1  8.3% 
Elderly + mild symptoms amenable to medications  1  8.3% 
Elderly + clinical debilitation from co-morbidities  1  8.3% 
Asymptomatic incidental finding on CTB   1  8.3% 
Extensive recurrent intracranial meningioma   1  8.3% 
Death before operative intervention    1  8.3% 
Total                   12  100% 
The reasons why some patients with clinically and radiologically suspicious intracranial 
meningiomas did not have operative intervention showed that 4 (33.3%) patients declined 
surgical removal of their brain tumour, 2 (16.7%) were elderly patients who were clinically 
debilitated from the brain tumour and therefore were not fit for surgical operation. The 
other reasons (1 (8.3%) patient each) for non-operative intervention are as shown in table 
3.3. 
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Table 3.4: Relative frequency of intracranial meningiomas among primary 
intracranial tumours 
 
Diagnosis                                           Number of patients              Percent 
Meningioma    48    33.8% 
Pituitary adenoma   35    24.6% 
Glioma        32    22.5% 
Craniopharyngioma   4    2.8% 
Ependymoma    4    2.8% 
Medulloblastoma   4    2.8% 
Schwannoma    3    2.1% 
Myeloma    3    2.1% 
Lymphoma     2    1.4% 
Epidemoid cyst   2    1.4% 
PCNSL    1    0.7% 
Meningeal haemangiopericytoma 1    0.7% 
Haemangioblastoma   1    0.7% 
Atypical teratoid/rhabdoid tumour 1    0.7% 
PNET     1    0.7% 
Total     142    100% 
Fourty eight (33.8%) patients had histologically confirmed intracranial meningioma during 
the study period, 35 (24.6%) had pituitary adenomas and 32 (22.5%) had gliomas. The rest 
of the intracranial tumours seen during the study period are as shown in Table 3.4. 
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Table 3.5: Age of patients at presentation 
 
Age group in years                          Number of patients              Percent 
Both genders 
21-30     4    8.3% 
31-40     9    18.7% 
41-50     20    41.7% 
51-60     13    27.1% 
61-70     2    4.2% 
Total     48    100% 
 
Males 
21-30     3    30% 
31-40     2    20% 
41-50     2    20% 
51-60     2    20% 
61-70     1    10% 
Total     10    100% 
 
Females 
21-30     1    2.6% 
31-40     7    18.4% 
41-50     18    47.4% 
51-60     11    29.0% 
61-70     1    2.6% 
Total     38    100% 
The mean (range) age of patients with intracranial meningiomas was 45.7 ± 10.5 (23-67) 
years with a median age of 46.5 years. The mean (range) age for male patients was 39.3 ± 
13.5 (23-61) years while that of female patients was 47.4 ± 9.0 (27-67) years.  
The peak age range was in the age group 41-50 years accounting for 41.7% of patients 
with meningiomas and corresponding to the fifth decade of life. The age group 51-60 years 
accounted for 13 patients (27.1%). Four patients (8.3%) were less than 30 years and only 2 
patients (4.2%) were over 60 yeaars of age. No patient was seen below 23 years. The 
relative frequency for males peaked in the third decade with 3 (30%) patients and for 
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females in the fifth and sixth decades with 18 (47.4%) and 11 (29.0%) patients 
respectively. 
Table 3.6: Gender, Race and Ethnic Nationality (Home language) distribution 
 
Variable                                           Number of patients              Percent 
Gender 
Male     10    20.8% 
Female    38    79.2% 
Total     48    100% 
 
Race 
Black     36    75% 
White     6    12.5% 
Coloured    4    8.3% 
Indian/Asian    2    4.2% 
Total     48    100% 
 
Ethnic Nationality (Home language) 
Sotho     13    27.1% 
Afrikaans    6    12.5% 
English    5    10.4% 
Zulu     5    10.4% 
Tshwana    5    10.4% 
Xhosa     5    10.4% 
Foreign National   4    8.3% 
Pedi     3    6.3% 
Tshivenda    1    2.1% 
Shangane    1    2.1% 
Total     48    100% 
Thirty eight (79.2%) patients were females and 10 (20.8%) were males. Thirty six (75%) 
patients were blacks, 6 (12.5%) were whites, 4 (8.3%) were coloured and 2 (4.2%) were 
Indians. Thirteen (27.1%) patients were of the Sotho ethnic nationality, 6 (12.5%) were 
Afrikaans and 5 (10.4%) patients accounted for English, Tshwana, Zulu and Xhosa ethnic 
nationalities. Three (6.3%) patients were Pedi and 1 (2.1%) each was Shangane and 
Tshivenda. There were 4 (8.3%) foreign nationals from neighboring Southern African 
countries.  
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Table 3.7: Presenting symptoms and signs 
 
Symptoms/signs                                Number of patients              Percent 
Headache    42    87.5% 
Visual impairment   31    64.6% 
Seizures    21    43.8% 
 Generalized  15(71.4%) 
 Focal   6(28.6%) 
Motor deficit    18    37.5% 
Dizzziness    17    35.4% 
Memory loss    12    25.0% 
Personality/behavioural changes 12    25.0% 
Other cranial nerve deficits  8    16.7% 
 Affected cranial nerves 
  VII  4(50.0%) 
  Multiple 3(37.5%) 
  VI  1(12.5%) 
Decreased GCS   9    18.8% 
Loss of smell    7    14.6% 
Gait problem    6    12.5% 
Vomiting    5    10.4% 
Hearing loss    5    10.4% 
Language problem   4    8.3% 
Neck stiffnes    4    8.3% 
Proptosis    4    8.3% 
Sensory loss    3    6.3% 
Extracranial mass/swelling  2    4.2% 
Cerebellar symptoms   2    4.2% 
Epistaxis    1    2.1% 
The order of prevalence of the presenting symptoms and signs of the patients is as shown 
in table 3.7. Headache (87.5%), visual impairment (64.6%), seizures (43.8%), motor deficit 
(37.5%), dizziness (35.4%), memory loss (25%), personality/behavioural changes (25%) 
and decreased GCS (18.8%) were noted in that order. These were followed by other cranial 
nerve deficits (16.7%), loss of smell (14.6%), gait problems (12.5%), vomiting (10.5%), 
hearing loss (10.5%), language problems (8.3%), neck stiffness (8.3%), proptosis (8.3%), 
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sensory loss (6.3%), extracranial mass (4.2%), cerebellar symptoms (4.2%) and epistaxis 
(2.1%).  
 
 
Figure 3.1: Mode of admission 
Forty patients (83.3%) were admitted as elective cases while 8 (16.7%) patients presented 
as emergencies.  
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Table 3.8: Characteristics of symptoms and signs at presentation and their duration  
 
Variable                                                            Number of patients      Percent         
First noticed symptoms (FNS) 
  Headache 20 41.7% 
Visual impairment 7 14.6% 
Loss of smell 5 10.4% 
Seizures 4 8.3% 
Personality/behavioural changes 3 6.3% 
Motor deficit 3 6.3% 
Proptosis 3 6.3% 
Decreasing LOC 1 2.1% 
Cranial nerve palsy 1 2.1% 
Extracranial mass/swelling 1 2.1% 
 
Neurosurgical consultation symptoms 
(NCS) 
Visual impairment 14 29.2% 
Motor deficit 8 16.7% 
Seizures 4 8.3% 
Personality/behavioural changes 4 8.3% 
Proptosis 4 8.3% 
Headache 3 6.3% 
Decreasing LOC  3 6.3% 
Uncontrollable seizures  2 4.2% 
Extracranial mass/swelling 1 2.1% 
Memory loss 1 2.1% 
Blindness 1 2.1% 
Cranial nerve palsy 1 2.1% 
Vomiting 1 2.1% 
Shortness of breath 1 2.1% 
Duration of FNS in months 
  <1 3 6.3% 
1-12 20 41.7%% 
13-24 13 27.1% 
25-36 5 10.4% 
37-48 1 2.1% 
49-60 1 2.1% 
>60 5 10.4% 
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Duration of NCS in months 
<1 19 39.6% 
1-12 25 52.1% 
13-24 2 4.2% 
The duration of symptoms varied widely, ranging from 1-120 months with a mean of 24.4 
± 26.5 months. On the average symptoms lasted for more than 24 months.  Twenty patients 
(41.7%) first noticed their symptoms (FNS) within 12 months while three patients (6.3%) 
noticed their symptoms within a month. The rest (25 patients) had symptoms longer than 
12 months. Headache (41.7%) was the first symptom to be noticed followed by visual 
impairment (14.6%) and loss of smell (10.5%).  
On the other hand, the duration of symptoms that necessitated neurosurgical consultation 
(NCS) were all within 24 months with 25 (52.1%) patients presenting within 12 months, 
19 (39.6%) within a month and only 2 (4.2%) patients presented in the second year. Visual 
impairment (29.2%) was the commonest symptom followed by motor deficit (16.7%) in 
that order.  
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Table 3.9: Anatomic location of intracranial meningiomas 
 
Radiological findings Number of patients Percent 
 
Anatomic Location 
Convexity     12   25.0% 
Olfactory groove    8   16.7% 
Sellar/suprasellar    7   14.6% 
Sphenoid wing    6   12.5% 
Falx      5   10.4% 
Spheno-orbital    3   6.3% 
Orbital      1   2.1% 
CP angle     1   2.1% 
Convexity-extracalvarial   1   2.1% 
Parasagittal     1   2.1% 
Intraventricular    1   2.1% 
Tentorial     1   2.1% 
Foramen magnum    1   2.1% 
Total                 48   100% 
 
Multiple meningiomas   4 (8.4%) 
            Spheno-orbital   2 
            Sellar/suprasellar   1 
            Olfactory groove   1 
 
Compartmental location 
Supratentorial     45   93.8% 
Infratentorial     3   6.3% 
All forty eight patients carried out CT scan and/or MRI of the brain as part of their pre-
operative investigation and work up. MRI had better definintion for these tumours and was 
able to detect somes cases with multiple tumours and dural tail. The anatomic location of 
the tumours is as shown in table 3.9. Convexity meningioma accounted for 25% of cases, 
olfactory groove 16.7%, sellar/suprasellar 14.6%, sphenoid wing 12.5%, falx 10.4% and 
spheno-orbital 6.3%. All spheno-orbitally located meningiomas presented with proptosis. 
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Meningiomas located at the cerebello-pontine angle (CPA), convexity-extracalvarial, 
parasagittal, intraventricular, tentorial and foramen magnum were found in 1 (2.1%) 
patient each. Four patients, however, had multiple tumours. Of these, two belonged to the 
spheno-orbital meningiomas, one each for sellar/suprasellar and olfactory groove 
meningiomas. The locations indicate the resection sites from which tissue biopsies were 
obtained. Supratentorially located tumours were the commonest (93.8%). 
Table 3.10: Radiological findings in patients with intracranial meningioma 
 
Variable                                                          Number of patients      Percent         
Radiologic findings 
  Enhancement 48 100% 
Mass effect 36 75% 
Oedema 30 62.5% 
Midline shift 24 50.0% 
Hydrocephalus 15 31.3% 
Hyperostosis 11 22.9% 
Dural tail 8 16.7% 
Bone destruction 5 10.4% 
 
Side of location 
  Left 22 45.8% 
Midline 15 31.3% 
Right 11 22.9% 
   Size of tumour 
  1-2cm 2 4.2% 
2-3cm 4 8.3% 
3-4cm 13 27.1% 
4-5cm 7 14.6% 
>5cm 22 45.8% 
Component of tumour 
  Solid 27 56.3% 
Solid + calcification 11 22.9% 
Solid + necrotic 4 8.3% 
Solid + cystic + necrotic 3 6.3% 
Solid + cystic 1 2.1% 
Solid + calcification + becrosis 1 2.1% 
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Solid + haemorrhagic 1 2.1% 
The order of prevalence of diagnostic radiological findings as well as tumour effects in the 
brain is as shown in table 3.10. Enhancement (100%), mass effect (75%), oedema (62.5%), 
midline shift (50%), hydrocephalus (31.3%), hyperostosis (22.9%), dural tail (16.7%), 
bone erosion (10.4%) were noted in that order.  Tumour location on the left side of the 
brain was seen in 22 (45.8%) patients, midline location in 15 (31.3%) patients while 11 
(22.9%) patients had their tumours located at the right side of the brain. The size of the 
tumours ranged from between 1-2cm in diameter to more than 5cm in diameter with the 
largest tumour sizes of >5cm in their longest dimension accounting for 45.8% of all the 
tumours. There were no tumours below 1cm in size among the resected cases except for 
those incidentally detected in the MRI of some of the patients with multiple tumours. Solid 
tumours constituted the highest (56.3%) in tumour component whereas among the mixed 
components, mixed solid tumour and calcification accounted for 22.9%. Mixed solid and 
haemorrhagic (acute haemorrhage) component was found in the only patient who 
presented in pregnancy.  
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Table 3.11: Histological subtypes and grading of intracranial meningiomas  
 
Variable                          Number of patients      Percent      
Histology result  
  
 
Meningothelial  19  39.6%  
 
Fibroblastic 7  14.6%  
 
Mixed meningiomas  7  14.6%  
 
Angiomatous, microcystic  2 (28.6%)  
 
 
Angiomatous, microcystic, 
secretory  1 (14.3%)  
 
 
Fibroblastic, fibroblastic, 
rhabdoid features  1 (14.3%)  
 
 
Meningotheliomatous, 
fibroblastic, microcystic  1 (14.3%)  
 
 
Transitional, meningothelial, 
fibroblastic  1 (14.3%)  
 
 
Transitional, fibroblastic, 
meningothelial and  
angiomatous    1 (14.3%)  
 
 
Transitional 4  8.3%  
 
Atypical 3  6.3%  
 
Anaplastic  2  4.2%  
 
Psammomatous  2  4.2%  
 
Chordoid  1  2.1%  
 
Clear cell 1  2.1%  
 
Microcystic  1  2.1%  
 
Secretory  1  2.1%  
 
WHO classification 
Grade I 39  81.3%  
 
Grade II 6  12.5%  
 
Grade III 3  6.3%  
 
Meningothelial meningioma accounted for 39.6% of cases followed by fibroblastic 
meningioma (14.6%), mixed meningiomas (14.6%), transitional (8.3%), atypical (6.3%), 
anaplastic (4.2%) and psammomatous meningiomas (4.2%) in that order. Chordoid, clear 
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cell, microcystic and secretory meningiomas accounted for 2.1% each. WHO classification 
grade I tumours were the commonest (81.3%). Though there were only 2 (4.2%) anaplastic 
tumours, the mixed meningioma with rhabdoid morphology confered to that tumour WHO 
grade III classification, hence the 3 (6.3%) WHO grade III tumours in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
28 
 
 
4.0 DISCUSSION 
There are few prospective studies on histologically proven intracranial meningiomas in the 
literature. This study therefore serves as a useful baseline study on intracranial 
meningiomas in our environment. Although the number of cases seen during the period of 
study remains the highest among the literatures reviewed and compared to in this study, the 
study is limited by the short period of 12 months. Hence the results were displayed in 
descriptive terms for comparison with other published data. 
4.1 Relative Frequency 
Meningiomas are estimated to constitute between 13-26% of primary intracranial 
neoplasms (42), though early combined results from several large hospital-based brain 
tumour studies showed that the incidence of meningiomas is approximately 20% of all 
intracranial tumours (11, 12, 22). In this study meningiomas accounted for 31.8% of all 
intracranial neoplasms and 33.8% of primary intracranial neoplasms. The findings in this 
study (33.8%) compares with a recent study by Idowu et al (21) in Ibadan (35%) and 
Idowu and Apemiye (43) in Lagos (30%) which showed high relative frequency of 
meningiomas among primary intracranial neoplasms in adults. It also compares with a 
recent study (44) in the United States (US) in which meningiomas accounted for 33.8% of 
all primary brain and central nervous system tumors reported in the United States between 
2002 and 2006. The findings also compares with a study by Das et al (45) in Singapore 
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(35.1%). The findings in this present study show that meningiomas are the most common 
primary intracranial tumours among adults in our environment. This, however, contrasts 
with reports indicating gliomas as the most common primary intracranial neoplasms in 
other series from Japan, Thailand, United States, and the previous USSR (45). 
When adjusted for number of patients per year, the findings (48 patients per year) in this 
study rates highest compared to that of Das et al (45) in Singapore (41 patients per year), 
Fynn et al (27) in Pretoria (17.3 patients per year), Gasparetto et al (46) in Brazil (15.6 
patients per year), Quiñones-Hinojosa et al (47) in US (9.6 patients per year), Francis (48) 
in India (6.9 patients per year) and Jaggon and Char (49) in Jamaica (5.3 patients per year). 
Although this may indicate a high trend in the relative frequency of intracranial 
meningiomas in our environment, it may also be the result of the improved detection rate 
through the increasing availability of modern diagnostic neuroimaging facilities in our 
environment.   
4.2 Sex   
Meningiomas affect women more often than men with a male-to-female ratio ranging from 
1:1.4 to 1:2.8 (29). This study showed a female-to-male ratio of 3.8:1 and compares with 
the findings of Idowu et al (21) which revealed a female-to-male ratio of 4.2:1 in both age 
group, and 4:1 in the adult population. It, however, contrasts with the findings of Jaggon 
and Char (49) in Jamaica (2.8:1), Fynn et al (27) in Pretoria (2.5:1) and Gasparetto et al 
(46) in Brazil (2:1). It is also a sharp contrast to Francis (48) in India (1.6:1) and Odebode 
et al (28) in Ibabdan (1.3:1). The findings in this study also differs from earlier 
observations in the literature (12, 29, 50), which reports equal gender distribution or a male 
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predominance among Africans. However, the female-to-male ratio of 1:3 in the third 
decade of life in this study is in keeping with reports in the literature which showed no 
predominance in women in their fourth decade and below (7, 12, 17). 
4.3 Race/Ethnicity 
Racial/ethnic differences in the prevalence of intracranial meningioma have been reported 
between Caucasians, Africans and African-Americans (29). The high frequency of 
intracranial meningiomas among the black race (75%) in this study may reflect the 
predominantly black population in our environment. However, among the other races, 
Indians had the lowest rate and there was no Asian, in keeping with the findings in other 
studies elsewhere (12, 31-33). In a recent US study (44), reported rates for Black Non-
Hispanics are slightly higher (6.67) than for White Non-Hispanic and Hispanics (5.90 and 
5.94, respectively). 
Meningiomas constituted 30% of brain tumors in Bantus in Africa (38). This compares 
with the high prevalence among Sotho ethnic nationality (27.1%) noted in our 
environment, despite the dominant ethnic group in Johannesburg being Zulu (10.4%). 
These findings may partly be explained on the influence of genetic factors on the 
prevalence of intracranial meningiomas in Johannesburg. The relative contributions of risk 
factors including environmental, hormonal or genetic factors to this sociodemographic 
variation are yet to be determined in our environment.  
4.4 Age   
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Meningiomas have a tendency to occur from the third to sixth decades of life (22, 38) and 
with peak incidence between the age of 40-60 years (51). Meningiomas are rare in patients 
younger than 20 years (38). This compares with the findings in our study which showed 
the peak age range in the fifth (41.7%) and sixth (27.1%) decade for both gender. Females 
showed similar peak age incidence of 47.4% and 29% respectively, whereas males had a 
fairly equal spread with the highest incidence in the third (30%) decade of life. There was 
no meningioma in infancy and childhood in this study. This is in keeping with the rarity of 
meningiomas in infants and children (7, 11, 22), though the short study period may have 
influenced this finding as well. 
The incidence of meningiomas increases with age (29). In this study, the youngest patient 
was 23 years old; the median age was 46.5 years while the mean age was 45.7 ± 10.1 
years.  This corresponds with the findings of Jaggon and Char (49) in Jamaica where the 
mean age of patients with intracranial meningiomas was 45 years. Fynn et al (27) in 
Pretoria found similar mean age (47 years) in their series. A lower mean age of 40 years 
was noted by Odebode et al (28) in Ibadan, though this may have been influenced by the 
low number of patients (n=35) in their study. A higher mean age of 52.7 years was noted in 
the study by Quiñones-Hinojosa et al (47) in the United States. However, their study 
assessed pre-operative factors affecting resectability of giant intracranial meningiomas (≥ 
5cm in the longest dimension). From their study, one can infer the likelihood of a shift 
towards older age group in large sized meningiomas. Large sized meningiomas are more 
likely to reflect long standing disease for these slowly growing tumours, and therefore their 
likely occurrence in the older age group. 
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When compared to other studies, the age range (23-67 years) in this study differs from that 
of Fynn et al (27) in Pretoria (2-83 years), Odebode et al (28) in Ibabdan (9-77 years), 
Jaggon and Char (49) in Jamaica (13-80 years) and Francis (48) in India (18-75 years). It 
compares to the findings of Gasparetto et al (46) in Brazil (23-81 years), in not having any 
patient in the paediatric age group but contrasts with it in not having any patient from the 
eight decade upwards. The absence of intracranial meningiomas in the paediatric age group 
in this study may have been influenced by the short study period, which may have limited 
the possibility of identifying patients in the paediatric age group within the study period. 
And the absence of intracranial meningiomas among patients from the eight decade 
upwards in this study may reflect a cautious approach to operative intervention among the 
elderly, as was reflected in the elderly constituting 33.3% (table 3.3) of patients among the 
reasons for non-operative intervention. 
4.5 Clinical Presentation 
The mean duration of symptoms for intracranial meningiomas has been reported to be 
approximately 15 months with 30% of complaints within 3 months in duration (38). This 
contrasts with the findings in this study where the mean (range) duration of symptoms and 
signs is 24.4 ± 26.5 (1-120) months with 6.3% of patients presenting within 1 month 
duration and 41.7% of patients within 12 months duration. The remaining 52% of patients 
presented after 12 months of symptoms. It is also a sharp contrast to the study by 
Quiñones-Hinojosa et al (47) where the median (range) duration of symptoms prior to 
diagnosis was 6 (2- 12) months, though it compares with the findings by Odebode et al 
(28) with a mean (range) duration of symptoms of 18 (2-60) months. One had expected a 
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longer duration of symptoms in the series by Quiñones-Hinojosa et al (47) on account of 
the larger tumour size (≥5cm) observed in their study which could reflect long standing 
lesions. This was, however, not the case. This may support the observation in the literature 
that late presentation and diagnosis remain serious issues in developing countries when 
compared to developed countries (28, 43). Probable reasons for this fact may be cultural 
and religious beliefs as well as self medication, financial constraints, low health education 
and low level of awareness even among clinicians (28, 43). However, large sized 
meningiomas, especially in the frontal lobes, can exist with few symptoms (38, 52) and 
this may contribute to the early presentation in the series by Quiñones-Hinojosa et al (47) 
despite the large tumour size. 
The primary complaints of patients include focal deficit, seizures, psycho-organic 
syndrome, and headaches (38). The most common symptoms and signs reported in the 
literature (53) are headache (36%), paresis (22%) and change in mental status (21%). This 
contrasts with the findings in the present study which showed headache (87.5%), visual 
impairment (64.6%), seizures (43.8%), motor deficit (37.5%) and dizziness (35.4%) as the 
commonest symptoms. The findings in this study, however, compares with that of 
Odebode et al (28) where the most common symptoms and signs were headache (91%), 
decreased visual aquity (85.7%), focal neurological deficits (59%), seizure (34.0%) and 
features of increased intracranial pressure other than headaches (32%). The high frequency 
of visual impairment in the present study differs from reports that visual loss is rare in 
olfactory groove, parasagittal, falx and convexity meningiomas but with a high association 
in sellar/suprasellar meningiomas because of close proximity of the latter to the optic 
nerves or chiasm and consequent pressure on the nerves (28). The high prevalence of 
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visual impairment in this study despite the wide distribution of the meningiomas 
throughout the cranium (table 3.9) may suggest the involvement of other influencing 
factors. The high prevalence of larger tumour size (45.8%), mass effect (75%), perifocal 
oedema (62.5%), and hydrocephalus (31.3%) (table 3.10) and, the resultant intracranial 
hypertension in addition to late presentation may act singly or in combination (28) as 
possible reasons for the high visual impairment noticed in this study. The symptom of 
epistaxis noticed in this study was in a HIV positive patient and may therefore be related to 
the systemic debilitation asssociated with HIV/AIDS symptomatology. 
Seizure activity is reported as one of the most common first presenting symptoms, with a 
frequency of 26% among patients with intracranial meningioma (10). In contrast when 
adjusted for First Noticed Symptom (FNS), headache (41.7%) was the first noticed 
symptom at presentation in our environment. This is closely followed by visual impairment 
(14.6%), anosmia (10.4%) and seizures (8.3%). This may have partly contributed to the 
issue of late presentation in our environment as the above symptoms are readily controlled 
on self-medication by patients, and as well easily misdiagnosed at initial presentation to 
primary care physicians as representing flu or refractory problems as the case may be. 
Further probing of the patients’ history in this study showed that the duration of symptoms 
that necessitated neurosurgical consultation (Neurosurgical Consultation Symptoms-NCS) 
were all within 24 months. Nineteen (39.6%) patients presented within 1 month of NCS 
while 25 (52.1%) patients presenting within 12 months and only 2 patients presented in the 
second year. Deterioration in vision (29.2%) was the commonest symptom followed by 
motor deficit (16.7%), seizures (12.5%) and behavioural changes (8.3%) in that order. This 
  
 
35 
may suggests that presentation to a neurosurgeon is highly influenced by the severity of the 
symptoms and signs as well as the degree of incapacitation to the patient. It may also give 
credence to similar observation and the assertion by Nkposong and Lawani (54) in their 
study on prostate cancer that the African has greater tolerance of symptoms. However, 
from personal observation noted by the author, the waiting time for diagnostic 
neuroimaging at public hospitals also contributes to some of the delays at presentation to 
neurosurgeons when radiodiagnostic requests are made by clinicians. 
4.6 Neuro-radiology 
The majority of focal extra-axial masses are meningiomas. In plain radiographs, their 
characteristic markers are hyperostosis, increased vascular markings and calcifications (13, 
53). No attempt was made in this study to use plain radiographs due to the availibility of 
modern neuroimaging in the two centres choosen for the study. The preferred investigation 
of choice for the diagnosis of intracranial meningioma is MRI because it has superior 
image resolution and can show more clearly the dural origin of the tumour in most cases 
(10, 52). Though CT scan remained the first choice in our environment because of the ease 
of accessibility and being more economical as a preliminary investigation for patients with 
neurological symptoms, MRI was employed where necessary to clear doubts on the 
radiological diagnosis.  
In 80% to 90% of cases, meningiomas have characteristic imaging appearances which 
guide diagnosis with confidence. The main diagnostic challenges include the distinction 
from dural metastasis, cerebral lymphoma, haemangiopericytoma, and extra-axial 
inflammatory conditions and infections such as sarcoidosis and tuberculosis; more rarely 
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gliomas and primitive neuroectodermal tumors may masquerade as meningiomas (10, 52). 
This was reflected in the findings in this study (table 3.2) which showed nine patients who 
were initially assessed as having meningiomas but who later had negative histology for 
meningiomas. The findings in this study show that metastatic tumour is the commonest 
differential diagnosis for intracranial meningiomas (33.3%) in our environment. Others 
include lymphoma (11.1%), myeloma (11.1%), tuberculosis (11.1%) and other primary 
intracranial neoplasms depending on the tumour location including haemangiopericytoma 
(11.1%). 
Some meningiomas show atypical features such as ring enhancement, central cystic 
degeneration or have an associated cyst that can mimic malignant intra-axial tumours (10, 
52). On the otherhand, meningioma can also be a differential diagnosis of other intracranial 
neoplasms depending on the location. Five of the patients in this study (table 3.1) were 
initially diagnosed with other types of intracranial neoplasms. The only case which was 
initially diagnosed as glioma but with histological diagnosis showing meningioma was the 
youngest patient (23 years) in this study. He presented as an emergency with severe 
clinical debilitation and a reduced GCS. CT scan showed a large (8.8cm in longest 
dimension) intra-axial left fronto-parietal inhomogeneously enhancing mass with areas of 
central necrosis and mild perifocal oedema. However, the histological diagnosis was a 
meningothelial meningioma (WHO grade I). The study shows that meningioma is a strong 
differential diagnosis for tumours thought to be pituitary tumours as well as a rare 
differential for some intra-axial tumours in our environment. However, MRI clearly 
distinguishes meningioma from other intracranial neoplasms in most cases by showing the 
presence of a dural-tail in meningiomas (52). Although dural tail is not pathognomonic, it 
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is possibly the best diagnostic sign (10, 53). Diagnosis of intracranial meningiomas can 
also be aided by the identification of anatomic interfaces (pial vascular structures, 
hypointense dura, cerebrospinal fluid clefts) between the tumor and brain surface. 
Cerebrospinal fluid clefts have high intensity on T2 weighted image and are therefore best 
for its visualization. Haemangiopericytoma is often confused with malignant meningioma 
(10). This is in keeping with the finding of haemangiopericytoma in this study (tables 3.1 
and 3.2). It featured both as a possible differential diagnosis of intracranial meningioma as 
well as meningioma being a differential diagnosis of haemangiopericytoma. Diagnostic 
differentiation is of clinical importance because haemangiopericytoma is associated with a 
more aggressive clinical course. Important features that are suggestive of 
haemangiopericytoma over meningioma include absence of calcification, lack of 
hyperostosis, bone destruction, and lobulated contour (10). 
Supratentorially located meningiomas constitute 85-90% with 5-10% infratentorially 
located (10, 53). This compares with the present study (93.8% and 6.3% respectively), 
Jaggon and Char (49) (87% and 4% respectively), Odebode et al (28) (94.3% and 5.7% 
respectively), and Quiñones-Hinojosa et al (47) (87% and 13% respectively). The sites for 
infratentorial meningioma include along the tentorial free edge, clivus, foramen magnum, 
petroclival ligament, and petrous ridge (10). The 3 infratentorially located meningiomas in 
this study were situated along the tentorial free edge, CPA and the foramen magnum and 
contrasts with the findings by Quiñones-Hinojosa et al (47) which were either along the 
cerebellar hemispheres or the CPA. It also contrasts with that of Jaggon and Char (49) 
which were attached to the falx cerebelli. The differences in the location of infratentorial 
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meningiomas in the different studies may be related to the rarity of meningiomas in this 
location. 
The most common locations include the convexity/parasagittal (45%), sphenoid ridge (15-
20%) and olfactory groove/planum sphenoidale (10%) (10, 53). This compares with the 
findings in this present study with convexity/falx/parasagittal accounting for 39.6%, 
sphenoid wing/spheno-orbital 20.9% and olfactory groove 16.7%. The findings of Fynn et 
al (27) and Jaggon and Char (49) also supports the above distribution of intracranial 
meningiomas in their studies. The prevalence of multiple meningiomas (5-40%) reported 
in the literature (29) also compares with the findings of multiple intracranial meningiomas 
(8.4%) in this present study. All the patients with spheno-orbital tumour location in this 
study in addition to the only orbitally located meningioma presented with proptosis, with 
one of the patients presenting with bilateral proptosis due to bilateral spheno-orbital 
meningioma. Intracranial meningioma should therefore be considered a strong differential 
diagnosis for proptosis in our environment. Meningiomas are reported to account for 6% to 
17% of diseases producing proptosis of the eye (55). Intracranial meningiomas of the 
greater and lesser wing of the sphenoid cause proptosis by different mechanisms including 
direct encroachment on the orbital cavity, by reactive hyperostosis of the inner orbital wall 
or by interfering with venous or lymphatic drainage (55). Classical optic nerve 
meningiomas results in proptosis devoid of ophthalmoplegia, visual failure, optic atrophy 
or papilloedema (55, 56). 
Meningiomas typically demonstrate intense enhancement after contrast administration both 
on CT scans and MRI (27, 46) and with the majority enhancing avidly and homogeneously 
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(10). This is in keeping with the findings in this study where all the meningiomas 
demonstrated enhancement (100%) with accentuation in over 56.3% of the cases and 
heteregeneous in the rest. This may be a possible reflection of the late presentation in our 
environment and the consequent large tumour sizes, long standing lesions and the attendant 
degenerative changes in the tumours. Gasparetto et al (46) noticed 83% and 64% 
respectively in their study.  
Meningiomas may also be associated with cystic components and calcification in some 
cases (27, 53). Peritumoral oedema, haemorrhage and central cystic degeneration may also 
be seen (52, 53). Hydrocephalus is uncommon because of the convex calvarial dural 
attachment of intracranial meningiomas, with the exception of intraventricular and 
posterior fossa locations (38). In addition, most meningiomas show a characteristic dural 
tail sign (35-80%) and hyperostosis which though uncommon in convexity meningiomas 
occurs in nearly 50% of skull-base tumours (10, 52, 53). On the otherhand, calvarial 
invasion may manifest with radiologic appearances of destruction and lysis. It is important 
to identify bone invasion as it guides decisions on treatment modality. Although bone 
invasion is thought to signify aggressive tumor behavior, it does not always correlate with 
the histologic morphology of meningiomas (10). 
The few cases of hyperostosis (22.9%) and dural tail (16.7%) in this study may be due to 
the low number of skull-base meningiomas and the limited use of MRI respectively. Bone 
destruction resulting from bone invasion was seen in 10.4% of cases in this study including 
the only patient with convexity-extrcalvarial meningioma. Contrary to reports in the 
literature, hydrocephalus was not uncommon (31.3%) in this study. The large (≥ 5cm in 
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longest dimension) size (45.8%) of meningiomas in this study and the associated marked 
mass effect (75%) in most cases, peritumoral oedema (62.5%), midline shift (31.3%) 
resulted in ventricular entrapment and hence hydrocephalus. These are all evidence of late 
presentation in our environment. Symptoms resulting from tumour haemorrhage are 
infrequent (38). The only patient who presented with tumour haemorrhage in this study 
was a post partum patient. She first presented to the obstetricians with pregnancy induced 
hypertension at 33 weeks of pregnancy. The development of fetal distres resulted in an 
emergency caesarean section being performed. She had a persistently reduced GCS 
postoperatively, necessitating an urgent CT scan of the brain which showed a large 
haemorrhagic (active haemorrhage) right frontal lobe mass. She subsequently had an 
emergency craniotomy and tumour excision afterwards which revealed an atypical 
meningioma. This supports the observation that meningiomas tend to have a more rapid 
growth rate during the later stages of pregnancy (10, 18, 57). It also supports reports in the 
literature noting the difficult clinical problem presented by the co-existence of brain 
tumour in preganacy because of their similar symptoms including headache, vomiting and 
visual impairment (58). Even convulsions caused by a brain tumour as well as rising blood 
pressure and reduced GCS (both resulting from raised intracranial pressure) may be 
erroneously attributed to pregnancy (58).  
The majority of the tumours in this study were located in the left side of the brain (45.8%), 
closely followed by midline location (31.3%) and the least being on the right side (22.9%). 
The implication is that our patients will be prone to tumour related morbidity and an 
attendant early presentation for neurosurgical consultation. The findings in this study 
showed significant tumour related mobidity including symptoms and signs of intracranial 
  
 
41 
hypertension (dizziness-35.4%, decreased GCS-18.8%, vomiting-10.4%), visual 
impairment (64.6%), seizures (43.8%), motor deficit (18%) and cranial nerve palsies 
(16.7%) among others (table 7). However, presentation to neurosurgeons was late and only 
16.7% of patients in this study were admitted as emergencies (table 8). The rest (83.3%) 
were admitted through the neurosurgical out-patient clinic. While this may add further 
credence to the observation by Nkposong and Lawani(54) that the African has greater 
tolerance of symptoms, it may also be related to low index of suspicion and consequent 
high level of misdiagnosis of intracranial meningiomas by most clinicians who see the 
patients first before referral for specialist care. 
4.7 Neuro-pathology 
The most commonly used grading system for meningiomas is that of the World Health 
Organization (WHO). The WHO classifies meningiomas into 3 grades: benign (WHO 
grade I), atypical (WHO grade II), and anaplastic or malignant (WHO grade III) and these 
constitute about 88-94%, 5-7% and 1-3% of cases respectively (10, 38, 52, 53). Therefore 
most meningiomas are benign tumours with the potential for cure after complete surgical 
excision. There is a range of subtypes based on their histological characteristics. However, 
the clinical behavior and outcomes correlate with the WHO grade, rather than the 
histological subtype. The grading of meningiomas is controversial, and accordingly there is 
a high incidence of interobserver variability (45). In this study WHO grade I constituted 
81.5% of cases followed by WHO grade II (12.5%) and WHO III (6.3%) in that order and 
contrasts with the rates reported in the literature. While this may reflect the influence of 
interobserver variability in the grading of meningiomas, it may also indicate a real 
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difference in the histological characteristics of meninigiomas between blacks and the rates 
reported in the literature. This may also indicate a need for a genome wide study of 
meningiomas in our environment likely to reveal valuable information at a high genomic 
resolution. In particular, it would be of value to assess copy number aberrations associated 
with the respective histological subtypes (typical, atypical, anaplastic) and with differing 
grade of tumors, in comparison to other published data (22). The findings in this study 
compares to that of Quiñones-Hinojosa et al (47) in the United States which showed 73% 
of tumours being WHO grade I, 19% WHO grade II and 7% WHO grade III. However, the 
restriction of their study to larger sized tumours (≥ 5cm) may have influenced their 
findings. The findings of Das et al(45) in Singapore (WHO grade I. 90.2%, grade II, 6.8% 
and grade III, 3% respectively) were in agreement with rates in the literature. Jaggon and 
Char (49) in Jamaica found 94% of tumours to be WHO grade I lesions and 6% of WHO 
grade III lesions in their study. While their findings may be interesting and reflect the role 
of genetic and environmental factors in tumour epidemiology across differing world 
regions, the difficulties in characterization of various histological subtypes and lack of 
consensus on diagnostic criteria may also play a role in their findings (45). 
Histological subtypes constituting WHO II include atypical, clear cell and chodoid 
subtypes and for WHO III they include the rhabdoid, anaplastic and papillary subtypes 
(53). WHO grade I meningiomas may have a variety of appearances, with the 
meningothelial, fibroblastic, and transitional variants occurring most commonly (10, 53). 
This is similar to the findings in this study (table 13). Similar findings were also noted by 
Odebode et al (28) and Jaggon and Char (49) in their studies. 
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 5.0 CONCLUSION 
Although this study did not aim at establishing the incidence of intracranial meningiomas 
in Johannesburg, it has shown that intracranial meningioma is not uncommon in 
Johannesburg. In fact, the relative frequency of intracranial meningiomas among primary 
intracranial neoplasms found in this study is one of the highest, and compares with other 
reports in the literature. Also the findings in this study agree with the observation that the 
highest incidence of intracranial meningiomas is in Africa when compared to other 
published data.   
The high relative frequency of intracranial meningiomas among primary intracranial 
neoplasms during the study period might be the result of the improved detection rate 
through the increasing availability of modern diagnostic neuroradiology in our hospitals.  
The peak age range at presentation of intracranial meningiomas in this study was in the 
fifth and sixth decades and is in agreement with most other studies. The female-to-male 
ratio of 3.8:1 is in keeping with the previous reports of female preponderance in 
intracranial meningiomas. 
Despite the high prevalence of intracranial meningiomas in our environment, patients 
presented late to neurosurgeons and tended to present when the symptoms and signs appear 
to be worsening, unbearable or incapacitating. This may reflect the observation in the 
literature that the African people have a greater tolerance of symptoms. 
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The majority of tumours were large in size with associated marked mass effect, 
peritumoral oedema and degenerative changes in most of the tumours. WHO grade I 
tumours were the commonest with meningothelial, fibroblastic and transitional histologic 
subtypes commonest as well, all in keeping with reports in the literature.  
Continuation of this prospective study and the expansion of the objectives to include 
genetic aspects of intracranial meningiomas, the methods of management and outcome in 
our environment need to be carried out to arrive at wide ranging conclusions. 
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6.0 RECOMMENDATION 
Genetic and environmental factors may be responsible for some of the findings in this 
study and therefore further study is required to identify these factors. Preferably a 
multicentre study in different cities in South Africa may help to have a clearer picture of 
the racial/ethnic epidemiology of this tumour in our environment. 
A much longer prospective study is strongly recommended to give the data stronger power 
for definite conclusions that will arise from the findings. 
Greater awareness of intracranial meningiomas should be created through widespread mass 
information of our population including clinicians.  
Visual problems and headache should be given serious consideration for diagnostic 
neuroimaging where symptoms remain unrelieved with basic care and medications. New 
onset headache and other symptoms and signs of brain tumours should raise a high index 
of suspicion in pregnant women as well.  
New onset seizures and motor deficits should remain absolute indications for diagnostic 
neuroimaging and accorded urgent status by neuroradiologists. 
A high index of suspicion for intracranial neoplasms should be given to neurologic 
symtoms and signs at presentation to clinicians and should also be considered urgent by 
neuroradiologist to reduce the waiting time by such patients for neuroimaging diagnosis. 
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APPENDIX A 
 
PRESENTATION OF INTRACRANIAL MENINGIOMAS IN JOHANNESBURG (A 12-
MONTH PROSPECTIVE STUDY AT CHARLOTTE MAXEKE JOHANNESBURG 
ACADEMIC HOSPITAL AND CHRIS HANI BARAGWANATH HOSPITAL, 
JOHANNESBURG) 
 
PRO FORMA OF STUDY 
BY 
DR IBEBUIKE, KE 
 
DATE: ….................      HOSPITAL NUMBER: ……………… 
 
A. DEMOGRAPHIC DATA (BASIC EPIDEMIOLOGY) 
 
 NAME & INITIALS: …………………  SERIAL NUMBER: ……........ 
 
1. Age at presentation        
2. Sex 
1. Male 
2. Female       
3. Race (Population Group)      
1. Black 
2. Coloured 
3. Indian       
4. White 
5. Others (please specify)...................................................... 
4. Home language 
1. Afrikaans  
2. English 
3. Pedi 
4. Sotho 
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5. Tswana 
6. Swati 
7. Xhosa 
8. Zulu 
9. Tshivenda 
10. Xishonga 
11. Ndebele 
12. Others (please specify)…………………………………  
 
5. Occupation  
1. Class I  -  Professionals and Business men 
2. Class II  - Lesser professionals, traders and teachers 
3. Class III N -  Skilled non-manual e.g. clerical staff 
4. Class III M  -  Skilled manual e.g. electrician, lorry drivers 
5. Class IV  -  Semi-skilled manual e.g. machine operators,  
                                                   farm workers  
6. Class V - Unskilled manual to the unemployed e.g.  
                                                Labourers 
 
6. Religious affiliation 
1. Christian 
2. Hindu 
3. Muslim 
4. Jehovah’s Witness 
5. Jewish 
6. None 
7. Others (please specify) 
    
7. Marital Status  
1. Single 
2. Married 
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3. Widow/er 
4. Divorced 
5. Separated 
 
 
8. Place of Domicile 
1. Urban 
2. Periurban (townships) 
3. Rural  
     
B. CLINICAL PRESENTATION 
 
 1. Headache        
 2. Seizures 
  1. Focal 
  2. Generalised 
 3. Neurological deficit 
  1. Cranial nerves 
  2. Long tracts 
  3. Mixed 
                     4. Others (please specify)............................................ 
4. Associations (please specify)……………………………….. 
5. Others (please specify)…………………………………… 
6. Duration of symptoms 
            7. Mode of admission 
  1.  Elective 
  2.  Emergency 
 
C. RADIOLOGY 
 
1. Location 
  
 
49 
2. Size 
3. Enhancement 
4. Oedema 
1. Widest margin less than tumour size 
2. Widest margin equals to tumour size 
3. Widest margin greater than tumour size 
4. No oedema 
5. Relationship to surrounding vascular structures 
           1.   Displacement of vessels 
           2.   Encasement of vessels 
6. Association with other intracranial pathology (please specify)…. 
7.  Others relevant findings (please specify)...................................... 
 
E. HISTOLOGY 
 1. Histological diagnosis 
 2. WHO classification                                                         
 3. Benign 
 4. Malignant 
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APPENDIX B 
PATIENT INFORMATION SHEET 
Title of study: Presentation of Intracranial Meningiomas in Johannesburg (A-12 month 
Prospective Study at Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani 
Baragwanath Hospital) 
Principal Investigator: Dr. K.E. Ibebuike 
Institute: Department of Neurosurgery, University of the Witwatersrand, Johannesburg 
Introduction: 
 I am Dr. K.E. Ibebuike from Department of Neurosurgery, University of the 
Witwatersrand, Johannesburg and doing a research on the presentation of intracranial 
meningiomas in Johannesburg. Since your brain scan shows that you are a patient likely to 
be suffering from this disease, I would like to invite you to join this research study. 
Background information 
Meningioma is a common brain tumour in the world and it is said to be commonest in 
Africa. It causes headache and many other symptoms depending on where it is located in 
the brain. The cause is not known for sure but there are some risk factors like previous 
exposure to x-rays, use of hormones as in oral contraceptives and even altered genes in our 
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body. There are many forms of management including surgery, radiotherapy and 
observation.  
Purpose of this research study 
The purpose of the study is to find out how common meningioma is in Johannesburg, how 
it is distributed in our population and the type of symptoms it causes in our patients.  
Procedures 
In this study, all patients from children to adults, presenting at the clinic or through 
emergency admission with brain tumour highly suspicious for meningioma will be 
considered for the study. A record of their demographic data, their symptoms including 
findings on brain scan will be kept for the study. As part of treatment some of the patients 
may undergo an operation where pieces of the tumour or even the whole tumour will be 
removed. The removed tumour will be sent to the histology laboratory in this hospital to be 
tested by scientists and doctors. This can help them diagnose your medical condition. 
Possible risks or benefits 
Collection of information is by our standard protocol in the routine assessment and care of 
our patients. No extra demands will be made on you. 
 There is no direct financial or other benefit for the participant of the study. However, any 
investigation which is specific for the study will be done free of cost to the patients.  
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Right of refusal to participate and withdrawal 
You are free to choose to participate in the study. You may refuse to participate without 
any loss of benefit which you are otherwise entitled to. You will receive the same standard 
care and treatment which is considered best for you irrespective of your decision to 
participate in the study. You may also withdraw any time from the study without any 
adverse effect on your management. You may also refuse to answer some or all the 
questions if you don’t feel comfortable with those questions.  
Confidentiality 
The information provided by you will remain confidential. Nobody except the investigator 
will have access to it. Your name and identity will also not be disclosed at any time. 
However the data may be seen by Ethical review committee and may be published in 
journal and elsewhere without giving your name or disclosing your identity. 
Available Sources of Information 
If you have any further questions you may contact the Investigator (Dr. K.E. Ibebuike), 
department of neurosurgery, University of the Witwatersrand, Johannesburg on the 
following phone number 0764931321.  
What do I have to do? 
You will need to give your written consent by signing an authorization. 
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APPENDIX C 
INFORMED CONSENT FORM 
Title of study: Presentation of Intracranial Meningiomas in Johannesburg (A-12 month 
Prospective Study at Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani 
Baragwanath Hospital) 
Principal Investigator: Dr. K.E. Ibebuike 
Institute: Department of Neurosurgery, University of the Witwatersrand, Johannesburg 
Introduction: 
 I am Dr. K.E. Ibebuike from Department of Neurosurgery, University of the 
Witwatersrand, Johannesburg and doing a research on the presentation of intracranial 
meningiomas in Johannesburg. Since your brain scan shows that you are a patient likely to 
be suffering from this disease, I would like to invite you to join this research study. 
Background information 
Meningioma is a common brain tumour in the world and it is said to be commonest in 
Africa. It causes headache and many other symptoms depending on where it is located in 
the brain. The cause is not known for sure but there are some risk factors like previous 
exposure to x-rays, use of hormones as in oral contraceptives and even altered genes in our 
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body. There are many forms of management including surgery, radiotherapy and 
observation.  
Purpose of this research study 
The purpose of study is to find out how common meningioma is in Johannesburg, how it is 
distributed in our population and the type of symptoms it causes in our patients.  
Procedures 
In this study, all patients from children to adults, presenting at the clinic or through 
emergency admission with brain tumour highly suspicious for meningioma will be 
considered for the study. A record of their demographic data, their symptoms including 
findings on brain scan will be kept for the study. As part of treatment some of the patients 
may undergo an operation where pieces of the tumour or even the whole tumour will be 
removed. The removed tumour will be sent to the histology laboratory in this hospital to be 
tested by scientists and doctors. This can help them diagnose your medical condition. 
Possible risks or benefits 
Collection of information is by our standard protocol in the routine assessment and care of 
our patients. No extra demands will be made on you. There is no direct financial or other 
benefit for the participant of the study. However, any investigation which is specific for the 
study will be done free of cost to the patients.  
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Right of refusal to participate and withdrawal 
You are free to choose to participate in the study. You may refuse to participate without 
any loss of benefit which you are otherwise entitled to. You will receive the same standard 
care and treatment which is considered best for you irrespective of your decision to 
participate in the study. You may also withdraw any time from the study without any 
adverse effect on your management. You may also refuse to answer some or all the 
questions if you don’t feel comfortable with those questions.  
Confidentiality 
The information provided by you will remain confidential. Nobody except the Investigator 
will have access to it. Your name and identity will also not be disclosed at any time. 
However the data may be seen by Ethical review committee and may be published in 
journal and elsewhere without giving your name or disclosing your identity. 
Available Sources of Information 
If you have any further questions you may contact the Investigator (Dr. K.E. Ibebuike), 
department of neurosurgery, University of the Witwatersrand, Johannesburg on following 
phone number 0764931321.  
AUTHORIZATION 
I have read and understand this consent form, and I volunteer to participate in this research 
study. I voluntarily choose to participate, but I understand that my consent does not take 
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away any legal rights in the case of negligence or other legal fault of anyone who is 
involved in this study. I further understand that nothing in this consent form is intended to 
replace any applicable laws.  
Participant’s Name:  
Date:  
Participant’s/Informant’s  Signature or thumb impression: 
Date:  
Principal Investigator’s Signature:  
Date:  
Signature of Person Obtaining Consent:  
Date:  
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